Monday , September 25 2017
Home / Technology & Devices

Technology & Devices

‘Labyrinth’ Chip Could Help Monitor Aggressive Cancer Stem Cells

ANN ARBOR–Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. It is already in use in a breast cancer clinical trial. Tumor cells isolated …

Read More »

Bristol-Myers Squibb and Halozyme Enter Collaboration and License Agreement for ENHANZE Technology

NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme’s ENHANZE® drug-delivery technology. “We are excited to partner with Halozyme to pursue potential new approaches to how our medicines are …

Read More »

Roche, Foundation Medicine Blood Test Could Help Personalize Cancer Immunotherapy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced presentations at the European Society for Medical Oncology (ESMO) Annual Meeting highlighting validation data for its novel assay to measure tumor mutational burden from blood (bTMB). These presentations will highlight retrospective data analysis from Roche/Genentech’s Phase II POPLAR and Phase III OAK studies …

Read More »

AstraZeneca Enters Respiratory Disease mRNA Collaboration with Ethris

MUNICH & GAITHERSBURG, Md.–(BUSINESS WIRE)–Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilised non-immunogenic modified RNA therapies for respiratory diseases …

Read More »

Fluidigm Licenses CFTR NGS Assay from Baylor Genetics for Use with the Juno System

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) and Baylor Genetics today announced that they have entered into a licensing agreement to offer a next-generation sequencing (NGS) library prep assay that enables efficient sequencing of the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Under the …

Read More »

Ligand Receives $2 Million from WuXi Biologics for Licensing anti-PD-1 Antibody Using OmniAb Technology

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and certain other territories. Ligand is also entitled …

Read More »

Biocept and UT Southwestern Medical Center Announce Study to Profile & Monitor NSCLC Cancer Patients with ALK Rearrangements

SAN DIEGO, Aug. 17, 2017 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces it has entered into a clinical study agreement with the University of Texas Southwestern Medical …

Read More »

Liquid Biopsies Find Distinct Genomic Profiles in Most Patients with Carcinoma of Unknown Primary

PHILADELPHIA — Next-generation sequencing of circulating tumor DNA (ctDNA) identified distinct genomic profiles with potentially targetable alterations in 99.7 percent of patients with carcinoma of unknown primary (CUP) who have detectable alterations, according to results published in Cancer Research, a journal of the American Association for Cancer Research. “Our research is the first …

Read More »

Takeda and Molecular Templates Collaborate for Next-Generation Oncology Therapies

OSAKA, Japan & AUSTIN, Texas–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) and Molecular Templates, Inc. today announced a collaboration agreement for oncology drug discovery programs. The collaboration will apply Molecular Templates’ engineered toxin bodies (ETB) technology platform to potential therapeutic targets provided by Takeda through a joint scientific committee of …

Read More »

Jazz Pharmaceuticals to Use XL-Protein’s Technology Platform to Develop Long-Acting Asparaginase Product Candidates

DUBLIN, July 26, 2017 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH (“XLp”) for the rights to develop, manufacture and commercialize products using XLp’s PASylation® Technology to extend the plasma half-life of selected asparaginase product candidates.  Under the …

Read More »